Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2005-10-04
2005-10-04
Scheiner, Laurie (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S211100, C530S300000
Reexamination Certificate
active
06951717
ABSTRACT:
Parainfluenza virus types 1 to 4 (PIV1 to PIV4) are important human pathogens that cause upper and lower respiratory tract infections, particularly in infants and children. The claimed invention is directed toward novel methods for the inhibition of parainfluenza virus transmission to a cell involving the administration of synthetic peptide fusion inhibitors. These inhibitors are derived from the parainfluenza virus and vary in length between 16 to 39 amino acids. The peptides were identified by screening for the presence of fusion inhibitory motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) within the parainfluenza virus genome. A number of peptides were identified and their fusion inhibitory activities ascertained. These peptides should provide useful antiviral agents.
REFERENCES:
patent: 4659669 (1987-04-01), Kleid et al.
patent: 4707358 (1987-11-01), Kieff et al.
patent: 5116725 (1992-05-01), Vaughan et al.
patent: 5141867 (1992-08-01), Ivanoff et al.
patent: 0323157 (1988-12-01), None
patent: 0 362 927 (1990-04-01), None
patent: WO 88/08429 (1988-11-01), None
patent: WO 89/02935 (1989-04-01), None
patent: WO 9007119 (1990-06-01), None
patent: WO 9109872 (1991-07-01), None
patent: WO 92/00997 (1992-01-01), None
patent: WO 9222654 (1992-12-01), None
Wild et al., 1992, Proc. Natl. Acad. Sci. USA, 89:10537-10541.
Bousse et al., 1995, Virol. 209:654-667.
Wildner, G., et al., 1997,“Database screening for molecular mimicry.”, Immunol. Today 18(5):251-252.
Baum, H., et al., 1997, “Also . . . ”, Immunol. Today 18(5):252-253.
Wild, C., et al., 1992, “A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition.”, Proc. Natl. Acad. Sci. USA 89:10537-10541.
Bousse, T., et al., 1995, “A single amino acid change enhances the fusion promotion activity of human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.”, Virol. 209:654-657.
Geysen, H. M., et al., 1988, “Cognitive features of continuous antigenic determinants.”, J. Molec. Recog. 1:33-41.
Benet, L. Z., et al., 1990, “Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination.”, in The Pharmacological Basis of Therapeutics, Goodman et al., eds., Pergamon Press, New York, pp. 1-33.
Yarchoan, R., et al., 1992, “Correlations between the in vitro and in vivo activity of anti-HIV agents: Implications for future drug development.”, J. Enzyme Inhib. 6:99-111.
Gait, M.J., et al., 1995, “Progress in anti-HIV structure-based drug design.”, TIBTECH 13:430-438.
Wild et al., 1992, “A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition”, Proc. Natl. Acad. Sci. USA 89:10537-10541.
Mitsuya et al., 1991, “Targeted therapy of human immunodeficiency virus-related disease”, FASEB J. 5:2369-2381.
Hammarskjold and Rekosh, 1989, “The molecular biology of the human immunodeficiency virus”, Biochem. Biophys. Acta 989:269-280.
Guyader et al., 1987, “Genome organization and transactivation of the human immunodeficiency virus type 2”, Nature 326:662-669.
Clavel et al., 1986, “Isolation of a new human retrovirus from west african patients with AIDS”, Science 233:343-346.
Maddon et al., 1986, “The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain”, Cell 47:333-348.
McDougal et al., 1986, “Binding of HTLV-III/LAV to T4 +T cells by a complex of the 110k viral protein and the T4 molecule”, Science 231:382-385.
Barin et al., 1985, “Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients”, Science 228:1094-1096.
Dalgleish et al., 1984, “The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus”, Nature 312:763-767.
Gallo et al., 1984, “Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS”, Science 224:500-503.
Klatzmann et al., 1984, “T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV”, Nature 312:767-768.
Teich et al., 1984, Pathogenesis of lentivirus, in “RNA Tumor Viruses”, Weiss et al., eds., CSH-Press, pp. 949-956.
Barre-Sinoussi et al., 1983, “Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)”, Science 220:868-870.
Chen, 1994, “Functional role of the Zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41”, J. Virology 68:2002-2010.
Carr and Kim, 1993, “Aspring loaded mechanism for the conformational change of influenza hemagglutinin”, Cell 73:823-832.
Songyang et al., 1993, “SH2 domains recognize specific phosphopeptide sequences”, Cell 72:767-778.
Lam et al., 1991, “The new type of synthetic peptide library for identifying ligand-binding activity”, Nature 354:82-84.
Lupas et al., “Predicting coiled coils from protein sequences”, Science 252:1162-1165.
Xu et al., 1991, “Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies”, J. Virology 65:4832-4838.
Chambers et al., 1990, “Heptad repeat sequences are located adjacent to hydrophobic regions in several typed of virus fusion glycoproteins”, J. Gen. Virology 71:3075-3080.
Malim et al., 1988, “Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes”, Nature 355:181-183.
Suzuki et al., 1995, “Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogenic and Syngeneic Tumors”, J of Experimental Medicine 182:477-486.
Wild et al., 1994, “Propensity for a Leucine Zipper-Like Domain of Human Immunodeficiency Virus Type 1 gp41 to Form Oligomers Correlates With a Role in Virus-Induced Fusion Rather Than Assembly of the Glycoprotein Complex”, Proc. Natl. Acad. Sci. USA 91:12676-80.
Bousse et al., 1994, “Regions in the Hemagglutinin-Neuraminidase Proteins of Human Parainfluenza Virus Type-1 and Sendai Virus Important for Membrane Fusion”, Virology 204:506-514.
Wang et al., 1993, “Ion Channel Activity of Influenza A Virus M2 Protein: Characterization of the Amantidine Block”, J. of Virology 67:5585-94.
Lazinski et al., 1993, “Relating Structure to Function in the Hepatitis Delta Virus Antigen”, J of Virology 67:2672-80.
White, J.M., 1992, “Membrane Fusion”, Science 258:917-924.
Daar et al., 1990, “High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates”, Proc. Natl. Acad. Sci. USA 87:6574-6579.
Erickson et al., 1990, “Design, Activity, and 2.8 Å Crystal Structure of a C2Symmetric Inhibitor Complexed to HIV-1 Protease”, Science 249:527-533.
Smith et al., 1987, “Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen”, Science 238:1704-1707.
Collins et al., 1984, “Nucleotide Sequence of the Gene Encoding the Fusion (F) Glycoprotein of Human Respiratory Syncytial Virus”, Proc. Natl. Acad. Sci. USA 81:7683-87.
Gallaher et al., 1989, “A General Model for the Transmembrane Proteins of HIV and Other Retroviruses”, AIDS Res. And Human Retroviruses 5:431-440.
Jiang et al., 1993, “Inhibition of HIV-1 Infection by a Fusion Domain Binding Peptide from the HIV-1 Envelope Glycoprotein gp41”, Biochem. Biophys. Res. Comm. 195:533-538.
Kingsbury, 1990, “Paramyxoviridae and Their Replication”, inVirology, 2ndEdition, Fields et al., eds., Raven Press, New York, p. 951.
Okamoto et al., 1988, “
Barney Shawn O'Lin
Lambert Dennis Michael
Petteway Stephen Robert
Parkin Jeffrey S.
Pennie & Edmonds LLP
Scheiner Laurie
Trimeris, Inc.
LandOfFree
Methods and compositions for inhibition of membrane... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of membrane..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of membrane... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3474751